rofecoxib and pyrroles
rofecoxib has been researched along with pyrroles in 8 studies
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Asch, SM; Escarce, JJ; Lewis, JH; Muñoz, JA; Rosen, MR; Schonlau, M; Yang, H | 1 |
| Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Heba, G; Legutko, J | 1 |
| Daminet, S; Fernandes, J; Martel-Pelletier, J; Moreau, M; Pelletier, JP | 1 |
| Hirota, T; Ikeda, T; Inoue, S; Kawai, K; Koyama, K; Oitate, M | 1 |
| Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
| Bechtold, NR; Cohen, EA; Downey, CR; Flewelling, SA; Greger, JG; MacDonald, JP; Pelkey, ET; Yoon-Miller, SJ | 1 |
| Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Kaur, G; Silakari, O | 1 |
Reviews
1 review(s) available for rofecoxib and pyrroles
| Article | Year |
|---|---|
Multiple target-centric strategy to tame inflammation.
Topics: Cyclooxygenase Inhibitors; Humans; Inflammation; Lactones; Lipoxygenase; Lipoxygenase Inhibitors; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrroles; Structure-Activity Relationship; Sulfones | 2017 |
Trials
2 trial(s) available for rofecoxib and pyrroles
| Article | Year |
|---|---|
High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Coronary Angiography; Cyclooxygenase Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Pyrroles; Sulfones; Treatment Outcome | 2004 |
Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dogs; Double-Blind Method; Duodenoscopy; Duodenum; Gastroscopy; Lactones; Lipoxygenase Inhibitors; Pyrroles; Stomach; Sulfones; Treatment Outcome | 2005 |
Other Studies
5 other study(ies) available for rofecoxib and pyrroles
| Article | Year |
|---|---|
Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; California; Cost Savings; Drug Costs; Drug Prescriptions; Health Expenditures; Heptanoic Acids; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Lactones; Medicare; Prescription Fees; Pyrroles; Sertraline; Sulfones; United States | 2002 |
Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
Topics: Animals; Aorta, Thoracic; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2 Inhibitors; Elastin; Lactones; Male; Protein Binding; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |
Synthesis of unsymmetrical 3,4-diaryl-3-pyrrolin-2-ones utilizing pyrrole Weinreb amides.
Topics: Alkenes; Amides; Boronic Acids; Catalysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Lactams; Lactones; Molecular Imaging; Molecular Probes; Molecular Structure; Pyrroles; Sulfones | 2011 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones | 2013 |